CureVac NV

CVAC · NASDAQ

$4.66−$0.01 (−0.21%)TodayMarket closed · Jan 5, 4:00 PM ET

No price history for this range.

CVAC analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Nov 14, 2025

Bull case

CureVac NV is strategically positioned within the competitive mRNA sector, leveraging the high value associated with COVID-19 vaccines to expand its portfolio into broader applications. The company demonstrates a strong pipeline with ongoing development programs, which include innovative mRNA vaccines for seasonal influenza, avian influenza, and oncology, indicating robust future revenue potential. As these initiatives progress according to plan, they enhance CureVac's long-term growth prospects and contribute positively to the company's overall financial outlook.

Bear case

CureVac is anticipated to continue incurring net losses at least until it achieves product approval and commercialization, which may extend into the early launch phase. The company faces significant competitive risks against both established products and in-development candidates, which could hinder its market position and future sales potential. Additionally, potential legal and intellectual property risks may further complicate its ability to capitalize on its pipeline, contributing to a challenging financial outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.